Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Purchases of Investments
Cash used to buy marketable securities and other investments.
Faeth Therapeutics, Inc.NASDAQ: FTH
Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026
Purchases of investments growth accelerates
Q2 FY2026 purchases of investments of $114.67M (cash outflow) rose 4605.2% year over year, ahead of the +394.3% change in trailing-twelve-month purchases of investments. Sequentially, it rose 161.2% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.
Context
- Purchases of investments grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4605.2% holds above the trailing-twelve-month pace of +394.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (25.16M) USD
- Year-over-year change
- +43.6%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.16M) | +43.6% |
| FY2024 | 2024-12-31 | (44.6M) | -110.9% |
| FY2023 | 2023-12-31 | (21.15M) | +54.9% |
| FY2022 | 2022-12-31 | (46.87M) | +74.5% |
| FY2021 | 2021-12-31 | (183.67M) | — |
Purchases of Investments vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's LTM Jun 2026 purchases of investments of $174.93M is the 5th largest of the 10 companies compared; the peer median is $151.68M.
- Its year-over-year change of +394.3% is the 2nd highest of 9, against a peer median of +14.3%.
- Over three fiscal years its annual growth of -18.7% compares with a peer median of +21.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.05B | +760.8% | +8.2% | — | |
| LTM Jun 2026 | $614.3M | +65.5% | -38.8% | 5935.2% | |
| LTM Mar 2026 | $446.68M | -32.7% | +33.8% | 2066.7% | |
| LTM Mar 2026 | $411.38M | -38.7% | +41.2% | 574.2% | |
| LTM Jun 2026 | $174.93M | +394.3% | -18.7% | — | |
| LTM Mar 2026 | $151.68M | -36.8% | +60.1% | — | |
| LTM Mar 2026 | $120.5M | +89.0% | +181.7% | 53.0% | |
| LTM Mar 2026 | $91.4M | +61.3% | -5.4% | 546.7% | |
| LTM Mar 2026 | $16.02M | — | — | 32.3% | |
| LTM Jun 2026 | $7.46M | -97.1% | -12.0% | 4.4% | |
| Peer median (excluding FTH) | $151.68M | +14.3% | +21.0% | 546.7% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Depreciation & Amortization | 685K | 1.35M | 1.35M | 1.32M | 139K |
| Deferred Income Tax | 19K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.66M | 5.81M | 4.45M | 3.14M | 1.27M |
| Change in Working Capital | 117K | 1.01M | (4.33M) | (489K) | (1.59M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.43M) | 2.02M | (2.33M) | (445K) | 233K |
| Other Working Capital | 1.54M | (1.01M) | (2M) | (44K) | (1.83M) |
| Other Non-Cash Items | 57K | 1.4M | 603K | 1.52M | 811K |
| Operating Cash Flow | (30.26M) | (39.03M) | (32.02M) | (24.67M) | (20.45M) |
| Capital Expenditures | (2.03M) | (321K) | (180K) | (146K) | (16K) |
| Acquisitions (Net) | 318K | 15K | 166K | 0 | 250K |
| Purchases of Investments | (183.67M) | (46.87M) | (21.15M) | (44.6M) | (25.16M) |
| Sales of Investments | 42.26M | 97.12M | 59.58M | 67.18M | 44.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.12M) | 49.95M | 38.41M | 22.44M | 19.77M |
| Debt Repayment | (255K) | (629K) | (761K) | (811K) | (648K) |
| Common Stock Issued | 140.59M | 342K | 48K | 34K | 7K |
| Common Stock Repurchased | 0 | 0 | (10.38M) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 109K | 0 | (76K) | (10K) | (3K) |
| Financing Cash Flow | 163.94M | (287K) | (11.17M) | (787K) | (645K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.44M) | 10.64M | (4.78M) | (3.02M) | (1.33M) |
| Free Cash Flow | (32.29M) | (39.35M) | (32.2M) | (24.82M) | (20.47M) |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.